Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and…

Overview of attention for article published in Frontiers in oncology, June 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (79th percentile)

So far, Dimensions has found 1 citation of this research output.

The most recent citing publication is shown below. View this citation on Dimensions.

Article in Reactions Weekly (August 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.